- Home
- HRMY vs BANR Comparison
HRMY vs BANR Comparison
Compare HRMY & BANR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | BANR |
|---|---|---|
| Founded | 2017 | 1890 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | HRMY | BANR |
|---|---|---|
| Price | $37.65 | $63.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $51.33 | ★ $71.20 |
| AVG Volume (30 Days) | ★ 701.7K | 193.4K |
| Earning Date | 11-04-2025 | 01-21-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | ★ 50.44 | 14.84 |
| EPS | 3.17 | ★ 5.49 |
| Revenue | ★ $825,944,000.00 | $640,027,000.00 |
| Revenue This Year | $23.11 | $0.96 |
| Revenue Next Year | $16.15 | $7.48 |
| P/E Ratio | $11.97 | ★ $11.67 |
| Revenue Growth | ★ 21.13 | 7.86 |
| 52 Week Low | $25.52 | $54.01 |
| 52 Week High | $40.93 | $72.58 |
Technical Indicators
Market Signals| Indicator | HRMY | BANR |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 42.37 |
| Support Level | $37.12 | $66.40 |
| Resistance Level | $39.60 | $67.95 |
| Average True Range (ATR) | 1.14 | 1.22 |
| MACD | -0.39 | -0.42 |
| Stochastic Oscillator | 15.47 | 3.01 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.